Sildenafil
Product Images NDC 50090-5802

10 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image -1 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 01)

Image -1 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 01)
Chemical structure of sildenafil, illustrating its molecular framework including heterocyclic rings and functional groups such as sulfonyl and tertiary amines, depicted with carbon, nitrogen, oxygen, and sulfur atoms.*
FDA Label Image

Image-2 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 02)

Image-2 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 02)
Line graph showing the effect of Sildenafil 100 mg versus placebo on systolic blood pressure (mmHg) over 24 hours post dose. The X-axis represents time post dose in hours, and the Y-axis shows systolic blood pressure changes. Two lines depict pressure changes for sildenafil and placebo groups.*
FDA Label Image

Image-3 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 03)

Image-3 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 03)
A line graph depicting the change in systolic blood pressure (SBP) over 8 hours post-dose. Two groups are compared: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg, with measurements plotted at various time points from 0 to 8 hours.*
FDA Label Image

Image-4 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 04)

Image-4 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 04)
A line chart showing the change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. It compares two treatments: Doxazosin with placebo and Doxazosin with Sildenafil 50 mg. The chart illustrates how SBP changes over time after administration of these treatments.*
FDA Label Image

Image-5 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 05)

Image-5 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 05)
A line graph depicting the change in mmHg over time (hours) after dosing, comparing two groups: Doxazosin plus Sildenafil 100 mg and Doxazosin plus Placebo. The vertical axis shows mmHg values, and the horizontal axis shows time from 0 to 8 hours after dosing.*
FDA Label Image

Image-6 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 06)

Image-6 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 06)
A plasma concentration versus time post dose graph depicting the pharmacokinetic profile of Sildenafil from a commercial tablet. The y-axis represents plasma concentration in ng/ml, and the x-axis shows time in hours post dose, illustrating the drug's concentration peak and subsequent decline over a 24-hour period.*
FDA Label Image

Image-7 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 07)

Image-7 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 07)
A bar chart titled 'Effect of Sildenafil on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint across different baseline scores (0 to 5). Each baseline score category includes multiple bars representing different numerical categories (0 to 5) indicated by a legend on the right side.*
FDA Label Image

Image-8 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 08)

Image-8 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 08)
A bar graph showing the effect of placebo on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis represents the percentage of patients at endpoint, ranging from 0 to 80%. Multiple bars for each baseline score correspond to different categories labeled 0 through 5, indicating variations in patient percentages across these scores.*
FDA Label Image

Image-9 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 09)

Image-9 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 09)
A bar chart comparing the percentage of patients reporting improvement across four treatment groups: Placebo, Sildenafil 25 mg, Sildenafil 50 mg, and Sildenafil 100 mg. The x-axis shows treatment groups with sample sizes, and the y-axis shows percentage improvement from 0 to 100%.*
FDA Label Image

Label Image (Lbl500905802)

Label Image (Lbl500905802)
SILDENAFIL 100 MG tablet label from A-S Medication Solutions. The label shows the active ingredient as sildenafil citrate equivalent to 100 mg sildenafil, storage instructions to keep at 68 to 77 degrees Fahrenheit, lot number, and packaging of 10 tablets. It also includes an NDC number 50090-5802-0 and directions to see package insert for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.